Issued Patents

Patent No. 8,747,890 for Intravenous Infusion of Curcumin and a Calcium Channel Blocker

Patent No. 8,753,674 for Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current

Patent No. 9,170,257 for Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Patent No. 8,784,881 for Liposomal Curcumin for Treatment of Diseases (Licensed from UTMD)

 

Publications

1. Lan Li, Fadi S, Braiteh FS et al.: Liposome encapsulated curcumin, in vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis.
Cancer 2005 104:1322-1331
(Click here for link)

2. Lan Li, Bilal Ahmed,Kapil Mehta et al.: Liposomal curcumin with and without oxaloplatin: effects on cell growth, apoptosis and angiogenesis in colorectal cancer.
Molecular Cancer Therapeutics. 2007 6:1276-1282
(Click here for link)

3. Savita Bisht, Georg Feldman, Scheetal Soni et al.: Polymeric nanoparticle encapsulated curcumin nanocurcumin: a novel strategy for human cancer therapy. J Nanobiotechnology 2007 5:3
(Click here for link)

4. Claire M Mach, Lata Matthew, Scott A Mosley, Lawrence Helson et al.: Determination of minimum effective dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer. Am Coll Clin Pharm.Annual meeting. 2008 Louisville KY. Presentation.
(Click here for link)

5. Clair M Mach, Lata Mathew, Scott A Mosley, et al.: Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Journal of Anticancer Research. 2009 29: 1895-1900
(Click here for link)

6. Clair M Mach, J.H.Chen, Sa Mosley et al. Evaluation of Curcumin Cytochrome p450 metabolism. Hematology Oncology Pharmacy Association(HOPA) June 17-20 ,2009. Abstract. Manuscript submitted J. Anticancer Research. 2010 in press.
(Click here for link)

7. Vishwanatha JK.: Biodegradable Nanoparticles for Cancer Therapy. 2nd Annual Unither Nanomedical and Telemedical Conference. Oreford Quebec, Canada Abstract presentation Feb 24-27 2009

8. MukerjeeA, and JK Vishwanatha: Formulation, Characterization and evaluation of Curcumin loaded PLGA nanospheres for cancer therapy. Journal of Anticancer Research 2009 29:3867-3876
(Click here for link)

9. Judith A Smith, Lata Mathew, MS Claire, K Santiago, L.Helson: Development of Liposomal curcumin as a new potential anticancer agent. MD Anderson Cancer Center and Signpath Pharma. AACR–EORTC-NCI 2009. Abstract and presentation Nov 18
(Click here for link)

10. Mukerjee A, Ranjan AP, Helson L et al: Formulation, Characterization and Evaluation of Annexin A2-conjugated curcumin loaded nanospheres as a targeted drug carrier system for breast cancer therapy. Proc.10thUS-Japan Symposium on Drug Delivery Systems. 2009 Maui, Hawaii. Ab no. 1468

11. Ranjan AP, Mukerjee A, JK Vishwanatha. Optimization of curcumin loaded PLGA nanoparticle-formulation using central composite design for cancer therapy. Proc. 10thUS-Japan Symposium on Drug Delivery Systems. 2009 Maui, Hawaii. Ab no 1526
(Click here for link)

12. Mukerjee A, Luchowski R, Ranjan et al.: Enhanced Fluorescence of curcumin on plasmonic platforms. Current Pharmaceutical Biotechnology. 2010 11:223-228
(Click here for link)

13. Lim KJ, Maitra A, Bisht S et al.: Using Nanocurcumin to treat Medulloblastoma and Glioblastoma. AACR Annual meeting Ab no.4440, 2010
(Click here for link)

14. Claire M Mach, Jing Hong Chen, Scott A Mosley: Evaluation of Liposomal Curcumin Cytochrome P450 Metabolism. Anticancer Research 2010 30:811-814
(Click here for link)

15. Mukerjee A, Sorenson T Thomas J et al.: Spectroscopic properties of curcumin, orientation of transition moments. J Physical Chemistry 2010 114:12679-12684
(Click here for link)

16. Bisht S,Mizuma M,Feldman G. et al.: Systemic Administration of Polymeric nanoparticle –encapsulated Curcumin(Nanocurc®) blocks tumor growth and metastases in preclinical models of Pancreatic Cancer. Mol Canc Ther. 2010 9: 2255-2264
(Click here for link)

17. Thamake S I, Iraut Sf, Ranjan AP,Gryczynski Z,and J K Vishwanatha.: Surface Functionalization of PLGA nanoparticles by non-covalent insertion of homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology 2011, 22(3):03510 (10pp)
(Click here for link)

18. Ray B, Bisht S, Maitra A, Maitra A, Lahiri, DK. Neuroprotective and Neurorescue Effects of a Novel Polymeric Nanoparticle Formulation of Curcumin (NanoCurc™) in the Neuronal Cell Culture and Animal Model: Implications for Alzheimer’s disease. J Alzheimers Disease. 2011 Jan 1;23(1):61-77
(Click here for link)

19. Helson L. Chiu S: Curcumin Formulations Brain Distribution. Presentation to MJFF for Parkinson’s disease NYC Sept 21, 2010.

20. Chiu SS, Lui E, Majeed M, Vishwanatha JK, Ranjan A, Maitra A, Dipanker P, Smith JA ,Helson L:Differential distribution of intravenous curcumin formulations in the rat brain. J Anticancer Research, 2011, 31(3):907-11.
(Click here for link)

20a. Yin-Meng Tsai, Chao-Feng Chien, Lie-Chwen Lin,Tung-Hu Tsai: Curcumin and its nano-formulation:The kinetics of tissue distribution and blood-brain barrier penetration. International Journal of Pharmaceutics, 2011 June 24th. (Click here for PDF)

21. Balmiki R, Bisht S, Maitra A et al. Neuroprotective and Neurorescue effects of a Novel Polymeric Nanoparticle Formulation of curcumin (NanoCurc®) in the Neuronal cell culture and Animal Model: Implications for Alzheimer’s disease. J Alzheimer’s Dis. 2011 23:61-77
(Click here for link)

22. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG: A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenecity, and stem-like fraction in malignant brain tumors. Cancer Biology and Therapy 2011, 11(5): 1-10
(Click here for link)

22a. Tuttle S, Hertan L, Katz JS: Indian gold treating cancer in the age of nano. Cancer Biology and Therapy, 2011, 11(5): 474-476 (a review of #22)
(Click here for link)

23. Savita Bisht, Mehtab A Khan, Mena Bekhit, Haibo Bai, Toby Cornish, Masamichi Mizuma, Michelle A Rudek, Ming Zhao, Amarnath Maitra, Balmiki Ray, Debomoy Lahiri, Anirban Maitra, and Robert A Anders. A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Laboratory Investigation (2011), 1–13
(Click here for link)

24. Lawrence Helson, George Shopp, Annie Bouchard, Muhammad Majeed. Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current. Journal of Receptor, Ligand and Channel Research, 2012
(Click here for link) (Click here for PDF)

25. LAWRENCE HELSON, GORDON BOLGER, MUHAMMED MAJEED, BRIGITTA VCELAR, KRESIMIR PUCAJ, and DHARMENDR MATABUDUL
Infusion Pharmacokinetics of Lipocurc™ (Liposomal Curcumin) and its Metabolite Tetrahydrocurcumin in Beagle Dogs.
Anticancer Res, 2012
(Click here for link) (Click here for PDF)

26. Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson and Jamboor K Vishwanatha Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. Journal of Nanobiotechnology, 2012
(Click here for link)

27. DHARMENDR MATABUDUL, KRESIMIR PUCAJ, GORDON BOLGER, BRIGITTA VCELAR, MUHAMMED MAJEED and LAWRENCE HELSON: Tissue Distribution of (LipocurcTM) Liposomal Curcumin and Tetrahydrocurcumin Following Two- and Eight-hour Infusions in Beagle Dogs. Anticancer Res, 2012
(Click here for link) (Click here for PDF)

28. Simon Chiu, Kristen J. Terpstra ,Yves Bureau,Jirui Hou, Hana Raheb, Zack Cernvosky, Vladimir Badmeav7 , John Copen; Mariwan Husni, Michael Woodbury: Liposomal-formulated curcumin[ LipocurcTM ] targeting HDAC (Histone Deacetylase ) , prevents apoptosis and improves motor deficits in Park 7 (DJ-1)- Knockout rat model of Parkinson’s disease : implications for Epigenetics-based Nanotechnology-driven Drug Platform.
(Click here for PDF)

29. Zou P, Helson L, Maitra A, Stern ST, McNeil SE Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.
(Click here for link) (Click here for PDF)

30. Poster “Safety and Pharamacokinetics of Liposomal Curcumin in Healthy Subjects: A Randomized Placebo_Controlled Double Blind First-in-human Study”
(Click here for poster)

31. Rajan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Res, 2013 Sep; 33(9):3603-9
(Click here for link)

32. Chun YS, Bisht S, Chenna V, Pramanik D, Yoshida T, Hong SM, de Wilde RF, Zhang Z, Huso D, Zhao M, Rudek M, Stearns V, Maitra A, Sukumar S. Intraductal Administration of a Polymeric Nanoparticle Formulation of Curcumin (NanoCurc) Significantly Attenuates Incidence of Mammary Tumors in a Rodent Chemical Carcinogenesis Model Implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis. 2012 Jul 25. [Epub ahead of print]
(Click here for link)

33. Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A, Maitra A. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012 Jun;3(6):640-50.
(Click here for link)

34. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol. 2009; 6:192-9.
(Click here for link)

35. Dr. Anirban Maitra, Dr Lawrence Helson Characterization of Nanocurcumin NCL 201304A
(Click here for link)

36. Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M. Effect of liposomal curcumin on red blood cells in vitro. Anticancer Res. 2013 Sep;33(9):3629-34
(Click here for link)

37. Amalendu P. Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha. University of North Texas Health Science Center, Fort Worth, TX. Targeted multifunctional lipid-PLGA hybrid nanosystems for metastatic breast cancer imaging and therapy. April 08, 2014
(Click here for link)

38. Shopp GM, Helson L, Bouchard A, Salvail D, Majeed M.Liposomes Ameliorate Crizotinib- and Nilotinib-induced Inhibition of the Cardiac IKr Channel and QTc Prolongation.
September 2014
(Click here for link)
(Click here for PDF)

39. Increased risk of Torsades de Pointes in streptozotocin-induced diabetic rats. Annie Bouchard*, Marie-Claude Benoit*, Sabrina Baillargeon*, Laurence Helson, George Shopp, Dany Salvail* November 2014
(click here for poster)
(click here for presentation)

40. Use of nanocurcumin to inhibit proliferation and metastases of hepatocellular carcinoma via NF-κB mediated matrix metalloproteinase-9 downregulation. J Clin Oncol 31, 2013 (suppl; abstr e22103) Author(s): Yang Xu, Bo Hu, Robert Anders, Anirban Maitra, Jia Fan; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Cancer Institute, Fudan University, Shanghai, China; The Johns Hopkins Hospital, Baltimore, MD; Johns Hopkins Hospital, Baltimore, MD
(Click here for link)

41. Safety, tolerability and pharmacokinetics of liposomal curcumin (LipocurcTM) in healthy humans.
Angela Storka1, Brigitta Vcelar2, Uros Klickovic1, Ghazaleh Gouya1, Stefan Weisshaar1, Stefan Aschauer1, Gordon Bolger4, Lawrence Helson3, and Michael Wolzt1
(Click here for PDF)

42. Curcumin Suppression of Cytokine Release and Cytokine Storm. A Potential Therapy for Patients with Ebola and Other Severe Viral Infections. PETER P. SORDILLO and LAWRENCE HELSON
(Click here for PDF)

43. Use of an Unconventional Approach to Boost Sensitivity and Improve Chromatography for Quantifying Curcumin and Tetrahydrocurcumin by LC-MS/MS.Aimin Tan; Yanxin Wu; Molly Wong; Albert Licollari; Gordon Bolger; John C. Fanaras; George Shopp; Lawrence Helson
(Click here for PDF)

44. Curcumin and Cancer Stem Cells: Curcumin Has Asymmetrical Effects on Cancer and Normal Stem Cells.
Peter P. Sordillo and Lawrence Helson. Anticancer Res. 2015 Feb;35(2):599-614.
(Click here for PDF)

45. Curcumin (diferuloylmethane) Delivery Methods: A Review Helson, L
(Click here for PDF)

46. Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson and Jamboor K Vishwanatha
(Click here for PDF)

47. Poster “Liposomal curcumin (LipocurcTM) and in vitro/in vivosurrogates for cytokine storm associated with uncontrolled EBOLA infection.”
(Click here for poster)

48. Abstract Effects of free curcumin and curcumin-liposomes (LipocurcTM) on pro-inflammatory cytokine expression in synovial fibroblasts and macrophages. Lukas Gober, Silvia Löbsch, Lawrence Helson, Andreas Wagner, Günter Steiner, Burkhard Klösch
(Click here for Abstract)

49. Poster “Utilizing Drug-Lipid Membrane Partitioning:  Novel, highly efficient and scalable loading of poorly water soluble drugs into the lipid membranes of preformed liposomes.”   Ehsan Suleiman, Andreas Wagner, Yvonne Perrie
(Click here for poster)

50. “Bifunctional role of pro-inflammatory cytokines after traumatic brain injury”  Peter P. Sordillo, Laura A. Sordillo & Lawrence Helson 
(Click here for PDF)

51. “Cerebral Cytokine Storm After Traumatic Brain Injury: Inflammatory Markers and Therapeutic Strategies” Peter P. Sordillo, M.D., Ph.D. and Lawrence Helson, M.D.
(Click here for Paper)